Issahy Cano

Issahy Cano

Auto-generated profile, based on publicly available information

Issahy Cano

Cornell University

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JYJinling Yang
Jinling Yang
MLMichelle E. LeBlanc
Michelle E. LeBlanc
ICIssahy Cano
Issahy Cano
KSKahira L. Saez-Torres
Kahira L. Saez-Torres
MSMagali Saint-Geniez
Magali Saint-Geniez
PDPatricia D'Amore
Patricia D'Amore
Contact between inflammatory cells and endothelial cells (ECs) is a crucial step in vascular inflammation. Recently, we demonstrated that the cell-surface level of endomucin (EMCN), a heavily O-glycosylated single transmembrane sialomucin, interferes with the interactions between inflammatory cells and ECs. We have also shown that, in response to an inflammatory stimulus, EMCN is cleared from the cell surface by an unknown mechanism. In this study, using adenovirus-mediated overexpression of a tagged EMCN in human umbilical vein ECs (HUVECs), we found that treatment with tumor necrosis factor-α (TNF-α) or the strong oxidant pervanadate leads to loss of cell-surface EMCN and increases the levels of the C-terminal fragment of EMCN (EMCN-CTF) 3-4–fold. Furthermore, treatment with the broad-spectrum matrix metalloproteinase (MMP) inhibitor batimastat (BB94) or inhibition of ADAM metallopeptidase domain 10 (ADAM10) and ADAM17 with two small-molecule inhibitors, GW280264X and GI254023X, or with siRNA, significantly reduced basal and TNF-α–induced cell-surface EMCN cleavage. The release of EMCN-CTF by the TNF-α treatment was blocked by chemical inhibition of either ADAM10 alone or in combination with ADAM17. These results indicate that cell-surface EMCN undergoes constitutive cleavage and that TNF-α treatment dramatically increases this cleavage, which is mediated predominantly by ADAM10 and ADAM17. As endothelial cell-surface EMCN attenuates leukocyte–EC interactions during inflammation, we propose that EMCN represents a potential therapeutic target to manage vascular inflammation.

3 January 2025 in Circulation Research
Verified
Journal Article
Open access
ZHZhengping Hu
Zhengping Hu
ICIssahy Cano
Issahy Cano
FLFengyang Lei
Fengyang Lei
JLJie Liu
Jie Liu
RRRamon Bossardi Ramos
Ramon Bossardi Ramos
PDPatricia D'Amore
Patricia D'Amore
BACKGROUND: EMCN (endomucin), an endothelial-specific glycocalyx component, was found to be highly expressed by the endothelium of the renal glomerulus. We reported an anti-inflammatory role of EMCN and its involvement in the regulation of VEGF (vascular endothelial growth factor) activity through modulating VEGFR2 (VEGF receptor 2) endocytosis. The goal of this study is to investigate the phenotypic and functional effects of EMCN deficiency using the first global EMCN knockout mouse model. METHODS: Global EMCN knockout mice were generated by crossing EMCN-floxed mice with ROSA26-Cre mice. Flow cytometry was used to analyze infiltrating myeloid cells in the kidneys. The ultrastructure of the glomerular filtration barrier was examined by transmission electron microscopy, whereas urinary albumin, creatinine, and total protein levels were analyzed from freshly collected urine samples. Expression and localization of EMCN, EGFP (enhanced green fluorescent protein), CD45 (cluster of differentiation 45), CD31, CD34, podocin, and albumin were examined by immunohistochemistry. Mice were weighed regularly, and their systemic blood pressure was measured using a noninvasive tail-cuff system. Glomerular endothelial cells and podocytes were isolated by fluorescence-activated cell sorting for RNA sequencing. Transcriptional profiles were analyzed to identify differentially expressed genes in both endothelium and podocytes, followed by gene ontology analysis. Protein levels of EMCN, albumin, and podocin were quantified by Western blot. RESULTS: The EMCN −/− mice exhibited increased infiltration of CD45 + cells, with an increased proportion of Ly6G high Ly6C high myeloid cells and higher VCAM-1 (vascular cell adhesion molecule 1) expression. EMCN −/− mice displayed albuminuria with increased albumin in the Bowman’s space compared with the EMCN +/+ littermates. Glomeruli in EMCN −/− mice revealed fused and effaced podocyte foot processes and disorganized endothelial fenestrations. We found no significant difference in blood pressure between EMCN knockout mice and their wild-type littermates. RNA sequencing of glomerular endothelial cells revealed downregulation of cell-cell adhesion and MAPK (mitogen-activated protein kinase)/ERK (extracellular signal–regulated kinase) pathways, along with glycocalyx and extracellular matrix remodeling. In podocytes, we observed reduced VEGF signaling and alterations in cytoskeletal organization. Notably, there was a significant decrease in both mRNA and protein levels of podocin, a key component of the slit diaphragm. CONCLUSION: Our study demonstrates a critical role of the endothelial marker EMCN in supporting normal glomerular filtration barrier structure and function by maintaining glomerular endothelial tight junction and homeostasis and podocyte function through endothelial-podocyte crosstalk.

11 April 2024 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
ICIssahy Cano
Issahy Cano
MWMelissa Wild
Melissa Wild
UGUrvi Gupta
Urvi Gupta
SCSuman Chaudhary
Suman Chaudhary
YNYin Shan Ng
Yin Shan Ng
ZHZhengping Hu
Zhengping Hu
The endothelial glycocalyx, located at the luminal surface of the endothelium, plays an important role in the regulation of leukocyte adhesion, vascular permeability, and vascular homeostasis. Endomucin (EMCN), a component of the endothelial glycocalyx, is a mucin-like transmembrane glycoprotein selectively expressed by venous and capillary endothelium. We have previously shown that knockdown of EMCN impairs retinal vascular development in vivo and vascular endothelial growth factor 165 isoform (VEGF165)-induced cell migration, proliferation, and tube formation by human retinal endothelial cells in vitro and that EMCN is essential for VEGF165-stimulated clathrin-mediated endocytosis and signaling of VEGF receptor 2 (VEGFR2). Clathrin-mediated endocytosis is an essential step in receptor signaling and is of paramount importance for a number of receptors for growth factors involved in angiogenesis. In this study, we further investigated the molecular mechanism underlying EMCN’s involvement in the regulation of VEGF-induced endocytosis. In addition, we examined the specificity of EMCN's role in angiogenesis-related cell surface receptor tyrosine kinase endocytosis and signaling. We identified that EMCN interacts with AP2 complex, which is essential for clathrin-mediated endocytosis. Lack of EMCN did not affect clathrin recruitment to the AP2 complex following VEGF stimulation, but it is necessary for the interaction between VEGFR2 and the AP2 complex during endocytosis. EMCN does not inhibit VEGFR1 and FGFR1 internalization or their downstream activities since EMCN interacts with VEGFR2 but not VEGFR1 or FGFR1. Additionally, EMCN also regulates VEGF121-induced VEGFR2 phosphorylation and internalization. Graphical Abstract

13 August 2026 in Biofabrication
Verified
Journal Article
Open access
SKSamantha E Kraus
Samantha E Kraus
ICIssahy Cano
Issahy Cano
SKSoo Jin Kim
Soo Jin Kim
ELEsak (Isaac) Lee
Esak (Isaac) Lee
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disorder that afflicts the synovial lining of joints and manifests in reduced range of motion, pain, swelling, and numerous other complications with no effective cure. In recent years, attention has shifted toward eradicating the source of synovial autoimmunity and inflammation, with a key focus on the synovial-draining lymphatics. However, very few in vitro models of the synovial microenvironment have been developed to date, and none yet include the synovial lymphatics. We therefore create a microfluidic chip device that models the synovial-draining lymphatics within the subintimal synovium microenvironment. Functional assays on our synovium-on-chip demonstrate increased lymphatic permeability and decreased drainage under RA inflammation compared to healthy controls, accompanied by increased lymphatic endothelial cell (LEC) junctional disruption and altered LEC phenotype following interaction with fibroblast-like synoviocytes. We identify overexpression of chitinase-3 like-protein-1 from RA patient-derived synoviocytes as a key target in inducing junctional loosening and lymphatic dysfunction, which is reversed in our microfluidic chip and in vivo mouse models by neutralizing antibody inhibition. Our novel synovium-on-chip model can provide a physiologically accurate representation of lymphatic drainage and activity under disease conditions, informing tissue engineering, drug testing, and high-throughput screening for RA.

8 October 2026 in Acta Biomaterialia
Verified
Journal Article
Closed access
LRLauren C. Richardson
Lauren C. Richardson
ICIssahy Cano
Issahy Cano
AKAnna M. Kolarzyk
Anna M. Kolarzyk
ELEsak (Isaac) Lee
Esak (Isaac) Lee

13 April 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAnthony Max Chen
Anthony Max Chen
ICIssahy Cano
Issahy Cano
QZQian Zhao
Qian Zhao
PTPei-Yin Tsai
Pei-Yin Tsai
EBElijah A. Bacchus
Elijah A. Bacchus
RWRobert Weiss
Robert Weiss
Triple-negative breast cancer (TNBC) is characterized by aggressive progression and poor prognosis, partly due to abnormal angiogenesis. While the metabolic reprogramming of tumor cells is well characterized, the metabolic regulation of tumor-associated endothelial cells (ECs) remains unclear. Here, we identified the mitochondrial deacylase SIRT5, which has established tumor-promoting roles in TNBC cells, as a key regulator of endothelial metabolic homeostasis and tumor angiogenesis. SIRT5-deficient host mice showed significant defects in supporting the growth of orthotopic SIRT5-proficient mammary tumor transplants, and the resulting neoplasms showed defects in tumor vascularization. In a 3D microfluidic vessel-on-chip model, SIRT5 loss compromised vascular barrier integrity and EC sprouting. Mechanistically, SIRT5 -deficient ECs exhibited diminished mitochondrial respiratory capacity but apparently normal glycolysis. SIRT5 loss also caused increased mitochondrial reactive oxygen species levels, and a mitochondrial antioxidant rescued the endothelial cell defects following SIRT5 loss, indicating that SIRT5-mediated mitochondrial redox homeostasis in the tumor microenvironment is necessary to maintain vascular function. Orthotopic co-transplantation of TNBC and EC cells with or without SIRT5 knockdown demonstrated that endothelial SIRT5 promotes increased tumor growth in vivo . These results suggest that targeting SIRT5 offers a potential therapeutic strategy to disrupt tumor angiogenesis and suppress TNBC progression by targeting the metabolic vulnerabilities of the tumor endothelium.